检索结果 - Anne Catherine Bretz

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activity

    C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activity 由 Markus Sauer, Anne Catherine Bretz, Rasa Beinoravičiūtė-Kellner, Michaela Beitzinger, Małgorzata Burek, Andreas Rosenwald, Greg S. Harms, Thorsten Stiewe

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)

    Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME) 由 Anne Catherine Bretz, Ulrike Parnitzke, Kerstin Kronthaler, Tobias Dreker, René Bartz, Frank Hermann, Astrid Ammendola, Tanja Wulff, Svetlana Hamm

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    The HDAC Inhibitor Domatinostat Promotes Cell-Cycle Arrest, Induces Apoptosis, and Increases Immunogenicity of Merkel Cell Carcinoma Cells

    The HDAC Inhibitor Domatinostat Promotes Cell-Cycle Arrest, Induces Apoptosis, and Increases Immunogenicity of Merkel Cell Carcinoma Cells 由 Lina Song, Anne Catherine Bretz, Jan Gravemeyer, Ivelina Spassova, Shakhlo Muminova, Thilo Gambichler, Ashwin Sriram, Soldano Ferrone, Jürgen C. Becker

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    DNA Binding Cooperativity of p53 Modulates the Decision between Cell-Cycle Arrest and Apoptosis

    DNA Binding Cooperativity of p53 Modulates the Decision between Cell-Cycle Arrest and Apoptosis 由 Katharina Schlereth, Rasa Beinoravičiūtė-Kellner, Markus Zeitlinger, Anne Catherine Bretz, Markus Sauer, Joël P. Charles, Fotini Vogiatzi, Ellen Leich, Birgit Samans, Martin Eilers, Caroline Kisker, Andreas Rosenwald, Thorsten Stiewe

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    CRISPR-Cas9–based target validation for p53-reactivating model compounds

    CRISPR-Cas9–based target validation for p53-reactivating model compounds 由 Michael Wanzel, Jonas B. Vischedyk, Miriam P. Gittler, Niklas Gremke, Julia R. Seiz, Mirjam Hefter, Magdalena Noack, Rajkumar Savai, Marco Mernberger, Joël P. Charles, Jean Schneikert, Anne Catherine Bretz, Andrea Nist, Thorsten Stiewe

    出版 2015
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: